Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 5/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580676 | 1.00 | PYGM (0.44) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL2583581 | 0.92 | PYGM (0.41) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL7212090 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL2581474 | 0.90 | RNASE1 (0.45) | TK1LMNARNASE1ALDH1A1ALB | |
| SCHEMBL7212087 | 0.90 | PYGM (0.50) | PYGMTK1P2RY6P2RY14BCHE | |
| SCHEMBL2581471 | 0.90 | RNASE1 (0.45) | TK1LMNARNASE1ALDH1A1ALB | |
| SCHEMBL2585686 | 0.88 | PYGM (0.43) | PYGMTK1P2RY6P2RY14LMNA | |
| SCHEMBL2588114 | 0.88 | KMT2A (0.39) | TK1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL2585372 | 0.88 | LMNA (0.46) | P2RY6P2RY14LMNATHRBSMN1; SMN2 | |
| SCHEMBL2575179 | 0.88 | PYGM (0.43) | PYGMTK1P2RY6LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1827457-A1 | URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067606-A1 | URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674104-A1 | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-28 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | PYGM 89/4885TK1 12/4885P2RY6 221/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | PYGM 4/4885TK1 35/4885P2RY6 377/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | PYGM 99/4885TK1 5/4885P2RY6 318/4885 |
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | NUDT1, UMPS, UPP1 | PYGM 1203/4885TK1 206/4885P2RY6 95/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | PYGM 72/4885TK1 12/4885P2RY6 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.